New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTriptorelin vs Follistatin 315

Triptorelin vs Follistatin 315

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Triptorelin
Anabolic & IGF
Follistatin 315
Summary
Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
Follistatin 315 is a splice variant isoform of follistatin produced by alternative mRNA processing. Unlike Follistatin 344 which is tethered to cell surfaces via heparan sulfate proteoglycans, FST-315 circulates freely in the bloodstream and has broader systemic distribution. It is the predominant circulating form and exerts systemic myostatin inhibition as well as FSH suppression, making it relevant to both muscle growth and reproductive endocrinology.
Half-Life
Depot forms: weeks to months; aqueous: 6-8 hours
~3–5 hours (longer systemic circulation vs FST-344)
Admin Route
SubQ, IM
SubQ, IM
Research
Typical Dose
100 mcg
No established human dosing protocol
Frequency
Single injection
Research use only
Key Benefits
  • Rapid HPG axis restart after steroid use
  • Single-injection PCT protocol possible
  • Massively elevates LH and FSH via flare effect
  • Restores endogenous testosterone faster than traditional PCT
  • FDA-approved for established medical uses
  • Systemic myostatin inhibition for whole-body muscle growth
  • Freely circulating — broader tissue distribution than FST-344
  • Strong FSH-suppressive activity useful in certain hormonal protocols
  • Potential for greater anabolic effect across multiple muscle groups simultaneously
  • May be more relevant to reproductive endocrinology applications
  • Studied in gene therapy approaches for muscular dystrophy
Side Effects
  • Initial testosterone flare (intended)
  • Injection site reactions
  • Hot flashes (with chronic use)
  • Decreased libido (chronic dosing)
  • Systemic FSH suppression — significant concern for fertility
  • Greater potential for off-target effects vs FST-344 due to systemic distribution
  • Limited human safety data
  • Potential cardiac hypertrophy with prolonged high-dose exposure
Stacks With